A new t(9;11;20;22)(q34;p11.2;q11.21;q11) in a Philadelphia-positive chronic myeloid leukemia case

Al-Achkar,Walid; Wafa,Abdulsamad; Liehr,Thomas

doi:10.3892/ol.2012.1039

A new t(9;11;20;22)(q34;p11.2;q11.21;q11) in a Philadelphia-positive chronic myeloid leukemia case

Authors:
- Walid Al-Achkar
- Abdulsamad Wafa
- Thomas Liehr
View Affiliations

Affiliations: Department of Molecular Biology and Biotechnology, Human Genetics Division, Atomic Energy Commission, Damascus, Syria, Jena University Hospital, Institute of Human Genetics, Jena, Germany
Published online on: November 21, 2012 https://doi.org/10.3892/ol.2012.1039
Pages: 605-608

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The so-called Philadelphia (Ph) chromosome is found in over 90% of cases of chronic myeloid leukemia (CML). Of these cases, 2-10% demonstrate complex translocations involving a third chromosome in addition to chromosomes 9 and 22. Since the majority of CML cases are currently treated with imatinib, variant rearrangements tend to have no specific prognostic significance, although the mechanisms involved in resistance to therapy have yet to be investigated. This study evaluated a CML case with complex chromosomal aberrations not previously observed. A four‑chromosome translocation involving chromosomal regions including 11p11.2 and 20q11.21 in addition to 9q34 and 22q11 was characterized in detail using array-proven multicolor banding (aMCB), a technique which has proven to be of significance in characterizing breakpoint regions in detail. Underlying mechanisms and prognostic factors are discussed.

View Figures

View References

1.	Johansson B, Fioretos T and Mitelman F: Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 107:76–94. 2002. View Article : Google Scholar : PubMed/NCBI
2.	Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B and Green AR: Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood. 95:738–743. 2000.PubMed/NCBI
3.	Huntly BJP, Bench A and Green AR: Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood. 102:1160–1168. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Reid AG, Huntly BJ, Grace C, Green AR and Nacheva EP: Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol. 121:419–427. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Bennour A, Sennana H, Laatiri MA, Elloumi M, Khelif A and Saad A: Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9. Cancer Genet Cytogenet. 194:30–37. 2009. View Article : Google Scholar
6.	Griffen J: The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol. 28:3–8. 2001. View Article : Google Scholar : PubMed/NCBI
7.	Kantarjian H, Sawyers C, Hochhaus A, et al: International STI571 CML Study Group: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:645–652. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Cortes JE, Talpaz M, Giles F, O’Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S and Kantarjian HM: Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 101:3794–3800. 2003. View Article : Google Scholar : PubMed/NCBI
9.	Claussen U, Michel S, Mühlig P, Westermann M, Grummt UW, Kromeyer-Hauschild K and Liehr T: Demystifying chromosome preparation and the implications for the concept of chromosome condensation during mitosis. Cytogenet Genome Res. 98:136–146. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Shaffer L, Slovak M and Cambell L: ISCN (2009): An International System for Human Cytogenetic Nomenclature. S. Karger; Basel: 2009
11.	Al-Achkar W, Wafa A and Nweder MS: A complex translocation t(5;9;22) in Philadelphia cells involving the short arm of chromosome 5 in a case of chronic myelogenous leukemia. J Exp Clin Cancer Res. 26:411–415. 2007.PubMed/NCBI
12.	Weise A, Mrasek K, Fickelscher I, Claussen U, Cheung SW, Cai WW, Liehr T and Kosyakova N: Molecular definition of high-resolution multicolor banding probes: first within the human DNA sequence anchored FISH banding probe set. J Histochem Cytochem. 56:487–493. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K, Weise A, Kuechler A and Claussen U: Microdissection based high resolution multicolor banding for all 24 human chromosomes. Int J Mol Med. 9:335–339. 2002.PubMed/NCBI
14.	Al-Achkar W, Wafa A, Ali BY, Manvelyan M and Liehr T: A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes. Oncol Lett. 1:797–800. 2010.PubMed/NCBI
15.	Mitelman F, Johansson B and Mertens F: Mitelman Database of Chromosome Aberrations in Cancer, 2009. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
16.	Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 268:884–886. 1995. View Article : Google Scholar : PubMed/NCBI
17.	Suzuki H, Dong JT, Gao AC, Barrett JC and Issacs JT: Identification of the rat homologue of KAI1 and its expression in Dunning rat prostate cancers. Prostate. 37:253–260. 1998. View Article : Google Scholar : PubMed/NCBI
18.	Yang X, Wei LL, Tang C, Slack R, Mueller S and Lippman ME: Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res. 61:5284–5288. 2001.PubMed/NCBI
19.	An Q, Wright SL, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Harrison CJ and Strefford JC: Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11∼13;q11) show recurrent involvement of genes at 20q11.21. Haematologica. 94:1164–1169. 2009.PubMed/NCBI
20.	An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Hall AG, Harrison CJ, Irving JA and Strefford JC: Variable breakpoints target PAX5 in patients with dicentric chromosomes: A model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci USA. 105:17050–17054. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Yamazaki H, Nakata T, Okada Y and Hirokawa N: KIF3A/B: a heterodimeric kinesin superfamily protein that works as a microtubule plus end-directed motor for membrane organelle transport. J Cell Biol. 130:1387–1399. 1995. View Article : Google Scholar : PubMed/NCBI
22.	Yamazaki H, Nakata T, Okada Y and Hirokawa N: Cloning and characterization of KAP3: a novel kinesin superfamily-associated protein of KIF3A/3B. Proc Natl Acad Sci USA. 93:8443–8448. 1996. View Article : Google Scholar : PubMed/NCBI
23.	Estes DA, Lovato DM, Khawaja HM, Winter SS and Larson RS: Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol. 139:20–30. 2007. View Article : Google Scholar
24.	Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, Reiter A, Hochhaus A and Cross NC; German Chronic Myelogenous Leukemia (CML) Study Group: Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood. 110:1283–1290. 2007. View Article : Google Scholar : PubMed/NCBI